Skip to main content
. Author manuscript; available in PMC: 2008 Apr 1.
Published in final edited form as: Mol Immunol. 2007 Feb 26;44(11):2884–2892. doi: 10.1016/j.molimm.2007.01.014

Fig. 1. Effect of SA-FasL on ex vivo treated cells at transfer.

Fig. 1

Fig. 1

Fig. 1

Spleens from NOD mice positive for diabetes were harvested, processed, and resuspended at 4×106/mL in complete MLR medium. Splenocytes were bulk cultured and treated with PBS, SA, or SA-FasL for 7.5 hours. Ex vivo treated cultures were analyzed for apoptosis (AnnexinV-FITC positive and 7-AAD negative) by flow cytometry. CD4+, CD4+CD25+, and CD8+ T-cell populations were analyzed for apoptosis using AnnexinV-FITC and T-cell antibodies: CD25-PE, CD8-PerCp, and CD4-APC. Effect of SA-FasL on ex vivo treated cells was statistically analyzed by Mann-Whitney U test. (A) Absolute number of live and apoptotic cells transferred. (B) Absolute number of CD4+ and CD8+ apoptotic cells transferred. (C) Absolute number of CD4+, CD4+CD25+, CD4+CD25-, and CD8+ live cells transferred. * P<0.01. †P<0.05.